Literature DB >> 10794582

Acute otitis media: part II. Treatment in an era of increasing antibiotic resistance.

M E Pichichero1.   

Abstract

Antibiotic resistance is increasing among the pathogens that commonly cause acute otitis media. This development may merit changes in the traditional antibiotic treatment of acute otitis media. Risk factors for resistant pathogens include recent antibiotic treatment of acute otitis media, children in day care facilities, wintertime infections and acute otitis media in children less than two years of age. Amoxicillin remains the antibiotic of first choice, although a higher dosage (80 mg per kg per day) may be indicated to ensure eradication of resistant Streptococcus pneumoniae. Oral cefuroxime or amoxicillin-clavulanate and intramuscular ceftriaxone are suggested second-line choices for treatment failure. Compliance with antibiotic regimens is enhanced by selecting agents that require less frequent dosing (such as one or two times a day) and by prescribing shorter (five days or less) treatment courses. Selective use of tympanocentesis if the patient does not respond to empiric therapy can help confirm the diagnosis and guide effective therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10794582

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  14 in total

1.  Diagnostic accuracy of otitis media and tympanocentesis skills assessment among pediatricians.

Authors:  M E Pichichero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-08-21       Impact factor: 3.267

2.  Management of acute otitis media.

Authors:  S Forgie; G Zhanel; J Robinson
Journal:  Paediatr Child Health       Date:  2009-09       Impact factor: 2.253

3.  The use of tympanocentesis in the diagnosis and management of acute otitis media.

Authors:  Michael E Pichichero; Tracy Wright
Journal:  Curr Infect Dis Rep       Date:  2006-05       Impact factor: 3.725

Review 4.  Cefuroxime axetil: an updated review of its use in the management of bacterial infections.

Authors:  L J Scott; D Ormrod; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Formulations for trans-tympanic antibiotic delivery.

Authors:  Xiaojuan Khoo; Emmanuel J Simons; Homer H Chiang; Julia M Hickey; Vishakha Sabharwal; Stephen I Pelton; John J Rosowski; Robert Langer; Daniel S Kohane
Journal:  Biomaterials       Date:  2012-11-09       Impact factor: 12.479

6.  Treatment of otitis media by transtympanic delivery of antibiotics.

Authors:  Rong Yang; Vishakha Sabharwal; Obiajulu S Okonkwo; Nadya Shlykova; Rong Tong; Lily Yun Lin; Weiping Wang; Shutao Guo; John J Rosowski; Stephen I Pelton; Daniel S Kohane
Journal:  Sci Transl Med       Date:  2016-09-14       Impact factor: 17.956

7.  Pharmacological treatment of acute otitis media in children. A comparison among seven locations: Tenerife, Barcelona and Valencia (Spain), Toulouse (France), Smolensk (Russia), Bratislava (Slovakia) and Sofia (Bulgaria).

Authors:  E Sanz; M A Hernández; M Kumari; S Ratchina; L Stratchounsky; M A Peiré; M Lapeyre-Mestre; B Horen; M Kriska; H Krajnakova; H Momcheva; D Encheva; I Martínez-Mir; V Palop
Journal:  Eur J Clin Pharmacol       Date:  2004-01-29       Impact factor: 2.953

8.  Otitis Media: A Review, with a Focus on Alternative Treatments.

Authors:  L M T Dicks; H Knoetze; C A van Reenen
Journal:  Probiotics Antimicrob Proteins       Date:  2009-03-04       Impact factor: 5.265

9.  Homeopathic medications as clinical alternatives for symptomatic care of acute otitis media and upper respiratory infections in children.

Authors:  Iris R Bell; Nancy N Boyer
Journal:  Glob Adv Health Med       Date:  2013-01

10.  Inactivation and sensitization of Pseudomonas aeruginosa by microplasma jet array for treating otitis media.

Authors:  Peter P Sun; Jungeun Won; Gabrielle Choo-Kang; Shouyan Li; Wenyuan Chen; Guillermo L Monroy; Eric J Chaney; Stephen A Boppart; J Gary Eden; Thanh H Nguyen
Journal:  NPJ Biofilms Microbiomes       Date:  2021-06-02       Impact factor: 7.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.